Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
This article examines conceptual limitations of extant accounts of palliative psychiatry, with a focus on obligations to distinguish among and clearly formulate goals of care.
AMA J Ethics. 2023;25(9):E710-717. doi:
10.1001/amajethics.2023.710.
S. Michelle Ogunwole, MD, PhD and Francheska D. Starks, PhD
Testimonial injustice is an expression of racism that uses identity to undermine individuals’ credibility as authoritative “knowers” of their own bodies, selves, and experiences.
AMA J Ethics. 2024;26(1):E72-83. doi:
10.1001/amajethics.2024.72.
Because health systems with high-functioning primary care services have decreased mortality and improved health outcomes, the sector can be classified as a public good, like police and fire services and public education.
AMA J Ethics. 2015;17(7):637-646. doi:
10.1001/journalofethics.2015.17.7.stas1-1507.